Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to -$1.3 billion.

  • UNITED THERAPEUTICS's Cash from Financing Activities fell 1391.42% to -$956.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 3.94%. This contributed to the annual value of -$1.3 billion for FY2024, which is 10444.54% down from last year.
  • According to the latest figures from FY2024, UNITED THERAPEUTICS's Cash from Financing Activities is -$1.3 billion, which was down 10,444.54% from -$11.9 million recorded in FY2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash from Financing Activities peaked at $75.4 million during FY2022, and registered a low of -$1.3 billion during FY2024.
  • Its 3-year average for Cash from Financing Activities is -$397.1 million, with a median of -$11.9 million in 2023.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Cash from Financing Activities surged by 365.09% in 2021 and then tumbled by 10,444.54% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash from Financing Activities (MRY) stood at -$16.9 million in 2020, then skyrocketed by 365.09% to $44.8 million in 2021, then surged by 68.30% to $75.4 million in 2022, then plummeted by 115.78% to -$11.9 million in 2023, then plummeted by 10,444.54% to -$1.3 billion in 2024.
  • Its last three reported values are -$1.3 billion in FY2024, -$11.9 million for FY2023, and $75.4 million during FY2022.